|Bid||82.17 x 4000|
|Ask||82.22 x 800|
|Day's Range||81.35 - 82.63|
|52 Week Range||74.13 - 139.72|
|Beta (3Y Monthly)||1.33|
|PE Ratio (TTM)||22.89|
|Earnings Date||Oct 25, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||111.65|
How's Celgene Positioned before Its Third-Quarter Earnings? Otezla’s net revenues grew from $358.0 million in the second quarter of 2017 to $375.0 million in the second quarter, which reflects ~4.7% growth YoY (year-over-year). In the US market, Otezla fell 4.9% YoY in the second quarter and reported revenues of $291.0 million.
A new survey examines the topic of brain volume loss, known as brain atrophy, in people with multiple sclerosis. The survey findings, presented at ECTRIMS 2018, suggest that there is a high level of interest in better understanding how brain atrophy may impact disease progression. The survey, conducted by the Multiple Sclerosis Association of America (MSAA) and sponsored by Celgene, included more than 1,300 people with multiple sclerosis or someone responding on their behalf.
The healthcare industry is watching the Trump presidency closely. President Trump's promise to repeal and replace Obamacare hit repeated stumbling blocks in Congress. Despite the uncertainty surrounding these efforts to overhaul the nation's healthcare system, a number of healthcare stocks rose dramatically throughout 2017.
How's Celgene Positioned before Its Third-Quarter Earnings? Celgene’s (CELG) hematology and oncology franchise consists of Revlimid, Pomalyst, Abraxane, Idhifa, Vidaza, Istodax, and Thalomid. Revlimid’s revenues grew from $3.9 billion in the first half of 2017 to $4.7 billion in the first half of 2018, which reflects ~19.6% growth YoY (year-over-year).
Wall Street analysts expect Celgene to report a net income and EPS of $1.2 billion and $1.71, respectively, in the third quarter.
Oct 10 (Reuters) - Beigene Ltd: * BEIGENE ANNOUNCES NATIONAL REIMBURSEMENT INCLUSION OF VIDAZA® (AZACITIDINE FOR INJECTION) BY THE STATE MEDICAL INSURANCE ADMINISTRATION IN CHINA * BEIGENE SAYS VIDAZA ...
Ozanimod showed effects on cognitive processing speed in a post hoc analysis of 12-month data from SUNBEAM™ pivotal trial
After narrowly dodging a corruption conviction, New Jersey Senator Bob Menendez faces a re-election dogfight against former Celgene CEO Bob Hugin. The Senator is now lying to voters about his opponent’s business record the way he dissembled about his political corruption. Democrats always treat a Republican candidate from business as if commerce is by definition criminal, and Mr. Hugin is no exception.
Neurocrine Biosciences’ (NBIX) revenues grew from $6.3 million in the second quarter of 2017 to $96.9 million in the second quarter. The company reported net revenues of $168.0 million in the first half of this year, which grew from $6.3 million in the first half of 2017. Wall Street analysts expect Neurocrine Biosciences to generate revenues of $151.8 million in the third quarter.
Celgene's (CELG) efforts to expand psoriasis drug, Otezla gets a boost as the late-stage study for the indication of plaque psoriasis of the scalp meets primary endpoint.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 8) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ...
Celgene Corporation (CELG) today announced results from the phase 3 STYLE study, which showed that OTEZLA® (apremilast) 30 mg twice daily achieved a highly statistically significant improvement in the primary endpoint of the Scalp Physician’s Global Assessment (ScPGA) response [defined as ScPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline] at week 16 compared with placebo. In addition to achieving the primary endpoint, statistical significance was also met for the secondary endpoint of the whole body itch numeric rating scale (NRS) [defined as at least a 4-point reduction from baseline] at week 16 with OTEZLA versus placebo. The safety profile was generally consistent with the known safety profile of OTEZLA, and no new safety signals were identified in the trial.
Cara Therapeutics (CARA) is a clinical-stage biotechnology company that develops new chemical entities for managing pain and pruritus. It reported EPS of -$0.52 on revenues of $2.87 million in the second quarter.
Ionis Pharmaceuticals’ (IONS) revenue stream is segregated into two segments: Research and Development revenues from the collaborative agreements with other companies, and Commercial Revenues. Commercial Revenues include licensing and royalty revenues and Spinraza royalties. The chart below compares the revenues for Ionis Pharmaceuticals since the first quarter of 2017.
Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Given Celgene's solid long-term track record, the lackluster year-to-date performance may represent a buying opportunity.
Cantor Fitzgerald has initiated coverage of Celgene Corp. (CELG) with an overweight rating. The analyst established a price target of $100 per share, which represents an 11.3% upside from the share price of $89.88 at close Monday. Warning! GuruFocus has detected 3 Warning Signs with CELG.
Celgene Corporation (CELG) will host a conference call and live audio webcast on Thursday, October 25, 2018 at 9 a.m. ET to discuss third quarter 2018 financial and operational results. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.